株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:糖尿病黄斑浮腫の疫学予測

EpiCast Report: Macular Edema - Epidemiology Forecast to 2026

発行 GlobalData 商品コード 312372
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.05円で換算しております。
Back to Top
EpiCast Report:糖尿病黄斑浮腫の疫学予測 EpiCast Report: Macular Edema - Epidemiology Forecast to 2026
出版日: 2017年11月01日 ページ情報: 英文 42 Pages
概要

黄斑浮腫(ME)は、網膜で中心視野を担う、黄斑の肥厚・腫脹(浮腫)が原因で発生します。世界の主要7ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)における糖尿病黄斑浮腫(DME)の発症件数は、2013年の922,492件から、今後10年間で1,238,301件まで、34.2%増加すると予測されています。

当レポートでは、世界の主要7ヶ国における糖尿病黄斑浮腫(DME)について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • 主要5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法 - 糖尿病と診断された患者数
    • 予測の前提条件と手法 - 糖尿病網膜症と診断された患者数
    • 予測の前提条件と手法 - 糖尿病網膜症と診断された患者数のうち、糖尿病黄斑浮腫(DME)と診断された患者数
    • 予測の前提条件と手法 - 網膜静脈分枝閉塞症(BRVO)・網膜中心静脈閉塞症(CRVO)に次ぐ、黄斑浮腫の総患者数
  • 黄斑浮腫の疫学予測
    • 糖尿病網膜症と診断された患者数のうち、DMEと診断された患者数
    • 糖尿病網膜症と診断された患者数のうち、DMEと診断された患者数:年齢別
    • 糖尿病網膜症と診断された患者数のうち、DMEと診断された患者数:性別
    • BRVOに次ぐ、MEの総患者数
    • BRVOに次ぐ、MEの総患者数:年齢別
    • BRVOに次ぐ、MEの総患者数:性別
    • CRVOに次ぐ、MEの総患者数
    • CRVOに次ぐ、MEの総患者数:年齢別
    • CRVOに次ぐ、MEの総患者数:性別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER169-17

Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as diabetic macular edema (DME). The risk for ME is also higher in patients with retinal vein occlusion (RVO), which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

GlobalData's epidemiological analysis is supported by the use of country-specific prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population and the total prevalent cases of ME following BRVO and CRVO, to allow for a meaningful comparison of the disease populations across these markets.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed retinopathy population will grow by 31.29% over the forecast period, at an Annual Growth Rate (AGR) of 3.13%, from 980,030 cases in 2016 to 1,286,637 cases by 2026. The total prevalent cases of ME following BRVO in the 7MM increased from 307,341 total prevalent cases in 2016 to 347,397 total prevalent cases in 2026. The total prevalent cases of ME following CRVO in the 7MM increased from 125,326 total prevalent cases in 2016 to 149,226 total prevalent cases in 2026, at an AGR of 1.91% during the forecast period.

Scope

  • The Macular edema (ME) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population, diagnosed prevalent cases of clinically significant DME among the diagnosed DME population, and the total prevalent cases of ME following BRVO and CRVO segmented by sex and age (ages 20 years and older) in these markets.
  • The ME epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The ME EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global ME market.
  • Quantify patient populations in the global ME market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ME therapeutics in each of the markets covered.
  • Understand magnitude of ME population by age and sex.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Executive Summary 5

  • 2.1 Related Reports 8
  • 2.2 Upcoming Reports 8

3 Epidemiology 9

  • 3.1 Disease Background 9
  • 3.2 Risk Factors and Comorbidities 10
  • 3.3 Global and Historical Trends 10
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 11
    • 3.4.2 Forecast Assumptions and Methods 16
    • 3.4.3 Diagnosed Prevalent Cases of T2D 16
    • 3.4.4 Diagnosed Prevalent Cases of T1D 20
    • 3.4.5 Diagnosed Prevalent Cases of Diabetic Retinopathy 20
    • 3.4.6 Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 21
    • 3.4.7 Diagnosed Prevalent Cases of Clinically significant DME Among the Diagnosed DME Population 22
    • 3.4.8 Total Prevalent Cases of BRVO and CRVO 23
    • 3.4.9 Total Prevalent Cases of ME following BRVO and CRVO 23
  • 3.5 Epidemiological Forecast for Macular Edema (2016-2026) 25
    • 3.5.1 Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 25
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 26
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 27
    • 3.5.4 Diagnosed Prevalent Cases of Clinically Significant DME Among the Diagnosed the DME Population 28
    • 3.5.5 Total Prevalent Cases of ME following BRVO 29
    • 3.5.6 Age-Specific Total Prevalent Cases of ME Following BRVO 30
    • 3.5.7 Sex-Specific Total Prevalent Cases of ME Following BRVO 31
    • 3.5.8 Total Prevalent Cases of ME following CRVO 32
    • 3.5.9 Age-Specific Total Prevalent Cases of ME Following CRVO 33
    • 3.5.10 Sex-Specific Total Prevalent Cases of ME Following CRVO 34
  • 3.6 Discussion 35
    • 3.6.1 Epidemiological Forecast Insight 35
    • 3.6.2 Limitations of Analysis 35
    • 3.6.3 Strengths of Analysis 36

4 Appendix 37

  • 4.1 Bibliography 37
  • 4.2 About the Authors 40
    • 4.2.1 Epidemiologist 40
    • 4.2.2 Reviewers 40
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 41
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 41
  • 4.3 About GlobalData 42
  • 4.4 Contact Us 42
  • 4.5 Disclaimer 42

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for DME 10
  • Table 2: 7MM, Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population, 2016 11
  • Table 3: 7MM, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, Ages ≥20 Years, N, Selected Years 2016-2026. 25
  • Table 4: 7MM, Diagnosed Prevalent Cases of Clinically Significant DME Among the Diagnosed DME Population, Both Sexes, Ages ≥20 Years, N, Selected Years 2016-2026 28
  • Table 5: 7MM, Total Prevalent Cases of ME following BRVO, Both Sexes, Ages ≥20 Years, N, Selected Years 2016-2026 29
  • Table 6: 7MM, Total Prevalent Cases of ME following CRVO, Both Sexes, Ages ≥20 Years, N, Selected Years 2016-2026 32

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, Ages ≥20 Years, N, 2016 and 2026 6
  • Figure 2: 7MM, Total Prevalent Cases of ME Following BRVO, Both Sexes, Ages ≥20 Years, N, 2016 and 2026 7
  • Figure 3: 7MM, Total Prevalent Cases of ME Following CRVO, Both Sexes, Ages ≥20 Years, N, 2016 and 2026 8
  • Figure 4: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D Among the General Population 12
  • Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of T1D Among the General Population 13
  • Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Diabetic Retinopathy Among the Diagnosed Diabetes Population 13
  • Figure 7: 7MM, Sources Used, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 14
  • Figure 8: 7MM, Sources Used, Diagnosed Prevalent Cases of Clinically-Significant DME Among the Diagnosed Diabetic Retinopathy Population 14
  • Figure 9: 7MM, Sources Used , Total Prevalent Cases of BRVO and CRVO Among the General Population 15
  • Figure 10: 7MM, Sources Used, Total Prevalent Cases of ME following BRVO 15
  • Figure 11: 7MM, Sources Used, Total Prevalent Cases of ME following CRVO 16
  • Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, N, 2016 26
  • Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Ages ≥20 Years, N, 2016 27
  • Figure 14: 7MM, Age-Specific Total Prevalent Cases of ME Following BRVO, Both Sexes, N, 2016 30
  • Figure 15: 7MM, Sex-Specific Total Prevalent Cases of ME following BRVO, Ages ≥20 Years, N, 2016 31
  • Figure 16: 7MM, Age-Specific Total Prevalent Cases of ME Following CRVO, Both Sexes, N, 2016 33
  • Figure 17: 7MM, Sex-Specific Total Prevalent Cases of ME following CRVO, Ages ≥20 Years, N, 2016 34
Back to Top